First Trust Advisors
VKTX icon

First Trust Advisors’s Viking Therapeutics VKTX Stock Holding History

First Trust Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-113,751
Closed -$4.44M – 2797
2026
Q2 		$4.44M Buy
113,751
+8,181
+8% +$264K ﹤0.01% 1654
2026
Q1 		$3.44M Buy
+105,570
New +$3.39M ﹤0.01% 1669
2024
Q4 		– Sell
-12,283
Closed -$778K – 2648
2024
Q3 		$778K Buy
+12,283
New +$721K ﹤0.01% 2074
2022
Q3 		– Sell
-102,755
Closed -$297K – 2615
2022
Q2 		$297K Sell
102,755
-4,173
-4% -$10.3K ﹤0.01% 2305
2022
Q1 		$321K Sell
106,928
-6,022
-5% -$21.6K ﹤0.01% 2360
2021
Q4 		$520K Buy
112,950
+14,014
+14% +$78.5K ﹤0.01% 2279
2021
Q3 		$621K Buy
+98,936
New +$611K ﹤0.01% 2212

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

First Trust Advisors's VKTX Position: Q3 2026 in Review

First Trust Advisors sold out of Viking Therapeutics (VKTX) in Q3 2026, closing a stake of 113,751 shares — an estimated $4.44M sold.

First Trust Advisors first reported a position in VKTX in Q3 2021 and held it in 7 quarters. The position peaked at $4.44M in Q2 2026. 322 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • First Trust Advisors reported no remaining Viking Therapeutics position as of Q3 2026 after selling out during the quarter.
  • First Trust Advisors sold 113,751 Viking Therapeutics shares in Q3 2026, an estimated $4.44M.
  • First Trust Advisors first reported a position in Viking Therapeutics in Q3 2021 and held it in 7 quarters.
  • First Trust Advisors's Viking Therapeutics position peaked at $4.44M in Q2 2026.
  • 322 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on First Trust Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.